Relay Therapeutics Inc Stock News

Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated  breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company's Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Re...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November: Guggenheim's 2nd Annual Healthcare Innovation Confe...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025.

Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI...

Relay Therapeutics, Inc. (NASDAQ:RLAY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Sanjiv Patel - CEO, President & Director Donald Bergstrom - President of Research & Development Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman...

Precision medicine specialist Relay Therapeutics (RLAY 3.25%) probably didn't want this holiday-shortened trading week to end, since it was quite the stock market star during the period. According to data compiled by S&P Global Market Intelligence, its share price climbed by almost 15%, thanks in no small part to a bullish new analyst note.

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: